Product/Composition:- | Ranolazine tablet |
---|---|
Strength:- | 500 mg and 1000 mg |
Form:- | Tablet |
Reference Brands:- | Ranexa(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Ranolazine inhibits late sodium current in cardiac cells, reducing calcium overload and improving myocardial efficiency. It decreases angina episodes, enhances exercise tolerance, and reduces oxygen demand. Benefits include better symptom control, improved cardiac function, and increased quality of life for patients with chronic angina.
Ranolazine tablets, marketed as Ranexa, are approved in the US by the FDA and in the EU via EMA for the treatment of chronic angina. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports timely approval, safe medication use, and global availability, helping millions manage angina and improve quality of life worldwide effectively.